# What happened to the trial in HIV-associated visceral obesity?

- Article ID: research-073
- Product: CJC-1295 With DAC (cjc-1295-with-dac-431, cjc-1295-with-dac-622, cjc-1295-with-dac-571)
- Canonical page: https://heritagebiolabs.com/research-library/articles/073-what-happened-to-the-trial-in-hiv-associated-visceral-obesity
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-with-dac
- Product page: https://heritagebiolabs.com/product/cjc-1295-with-dac-431
- Product page: https://heritagebiolabs.com/product/cjc-1295-with-dac-622
- Product page: https://heritagebiolabs.com/product/cjc-1295-with-dac-571
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2005, 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides consist of short chains of amino acids joined by peptide bonds. An engineered peptide can copy part of a natural hormone signal, making it possible to ask a specific clinical question. CJC-1295 With DAC is a growth hormone–releasing hormone analogue with a protein-binding attachment called a drug affinity complex. A historical phase 2 trial asked whether CJC-1295 could affect visceral obesity in people with HIV. [1, 2]

No recent primary results for that question were identified. The older trial registry describes a randomized, double-blind, placebo-controlled study in people with HIV and excess visceral fat, which is fat stored around internal organs. The registry uses the name CJC-1295 without specifying the precise form. The FDA's historical review linked the development program to the DAC compound and noted that the trial was terminated. The FDA also reported that a participant died after an acute heart attack and that the available trial data had not been published. The available record does not establish that the compound caused the event. [1, 2]

A study registration records the question the researchers set out to answer and how they planned to compare groups. To evaluate the answer, readers would need to know how many people completed the study, what the groups experienced, and what was measured in each group. A terminated trial with no published results leaves those comparisons unresolved. Early experiments on hormone concentrations in healthy adults cannot fill that gap. [1, 2]

The investigation concerns one proposed indication and one development program. The FDA's review identified no approved CJC-1295 drug. The registry is evidence that the clinical question was investigated, while the FDA briefing documents the limits of what the trial can establish. [1, 2]

## Sources

1. ConjuChem. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov (first posted 2005-12-21, estimated). <https://clinicaltrials.gov/study/NCT00267527>
2. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 015 - CJC-1295 With DAC and CJC-1295 (No DAC) GHRP-2.docx; article 73; content SHA-256 53ad189c3ade35f758e606801284dbdb93bb3de6f954cb8c708b5f03860e295d.
